Evidence map›Paper›PMID 41317182›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Impact of disease-modifying therapy on [

Clemens P Spielvogel, Markus Köfler, Zewen Jiang, Jing Ning, Josef Yu, David Haberl, Christina Kronberger, Michael Poledniczek, Lena Marie Schmid, David Kersting and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Clemens P SpielvogelDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Spitalgasse 23, Vienna, A-1090, Austria. clemens.spielvogel@meduniwien.ac.at.ORCID 0000-0002-4409-8324
Markus KöflerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Spitalgasse 23, Vienna, A-1090, Austria.
Zewen JiangDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Spitalgasse 23, Vienna, A-1090, Austria.
Jing NingDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Spitalgasse 23, Vienna, A-1090, Austria.
Josef YuDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Spitalgasse 23, Vienna, A-1090, Austria.
David HaberlDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Spitalgasse 23, Vienna, A-1090, Austria.
Christina KronbergerDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Michael PoledniczekDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Lena Marie SchmidDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
David KerstingDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg- Essen, Essen, Germany.
Nikita ErmolaevDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Roza B EslamDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Michaela Auer-GrumbachDepartment of Orthopedics and Trauma Surgery, Medical University of Vienna, Vienna, Austria.
Christina BinderDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Franz DucaDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Christian NitscheDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Johannes KastnerDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Jutta Bergler-KleinDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Andreas A KammerlanderDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Christian HengstenbergDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Marcus HackerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Spitalgasse 23, Vienna, A-1090, Austria.
Raffaella CalabrettaDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Spitalgasse 23, Vienna, A-1090, Austria.
René RettlDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTransthyretin cardiac amyloidosis (ATTR-CM) is a progressive, underdiagnosed disease with high morbidity and mortality. While disease-modifying therapies (DMTs) slow progression, early treatment response markers remain scarce. This study assessed AI-quantified thoracic [

methodsThis longitudinal study included ATTR-CM patients receiving DMTs (transthyretin stabilizers, RNA interference, or antisense oligonucleotides). [

resultsIn 45 patients (37 ATTRwt-CM, 8 ATTRv-CM), 65% (17/26) of AI-extracted SPECT/CT markers significantly decreased after treatment (all p < 0.001), including SUV

conclusionAI-driven [

Indexed as

Amyloid Neuropathies, FamilialArtificial IntelligenceOrganotechnetium CompoundsSingle Photon Emission Computed Tomography Computed TomographyAgedAged, 80 and overBiomarkersDiphosphonatesFemaleHumansLongitudinal StudiesMaleMiddle AgedBiomarkersDiphosphonatesOrganotechnetium Compoundstechnetium Tc 99m 1,1-diphosphonopropane-2,3-dicarboxylic acidArtificial intelligenceCardiac amyloidosisSPECT/CTTransthyretinTreatment response

Identifiers

PMID41317182
PMCPMC13013229

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.